Comparative in vitro activity of garenoxacin against Chlamydia spp
The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2002-09, Vol.50 (3), p.407-410 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 410 |
|---|---|
| container_issue | 3 |
| container_start_page | 407 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 50 |
| creator | Donati, M. Pollini, G. M. Sparacino, M. Fortugno, M. T. Laghi, E. Cevenini, R. |
| description | The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined. |
| doi_str_mv | 10.1093/jac/dkf145 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72040136</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>325349651</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-23d92e41c64c193ac499227db54265ce6b05a2c22998e20bb115195ede5f85403</originalsourceid><addsrcrecordid>eNqFkE1rGzEQhkVJqZ2kl_6AsOTQQ2DrGX3t6hibJg4NBNq0lF6EVqt1ZHs_Iq2D_e-zwSaBXnIahvfhHeYh5AvCNwTFJktjJ-WqQi4-kDFyCSkFhUdkDAxEmnHBRuQ4xiUASCHzT2SElIIAmY3JdNbWnQmm908u8U3y5PvQJsYOu-93SVslCxNc026NHVKzML6JfTJ7WJt6V3qTxK47JR8rs47u82GekN9X3-9n8_T27vpmdnmbWo6iTykrFXUcreQWFTOWK0VpVhaCUymskwUIQy2lSuWOQlEgClTClU5UueDATsjXfW8X2seNi72ufbRuvTaNazdRZxQ4IJPvgpjzjOcyH8Dz_8BluwnN8ISmmEnJAF_OXuwhG9oYg6t0F3xtwk4j6Bf_evCv9_4H-OzQuClqV76hB-EDkO4BH3u3fc1NWOkhzYSe__2n8-mPqz_8J-hf7BmSKI6Z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>217663010</pqid></control><display><type>article</type><title>Comparative in vitro activity of garenoxacin against Chlamydia spp</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Free Full-Text Journals in Chemistry</source><creator>Donati, M. ; Pollini, G. M. ; Sparacino, M. ; Fortugno, M. T. ; Laghi, E. ; Cevenini, R.</creator><creatorcontrib>Donati, M. ; Pollini, G. M. ; Sparacino, M. ; Fortugno, M. T. ; Laghi, E. ; Cevenini, R.</creatorcontrib><description>The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.</description><identifier>ISSN: 0305-7453</identifier><identifier>ISSN: 1460-2091</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkf145</identifier><identifier>PMID: 12205067</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject><![CDATA[Animals ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Chlamydia Infections - drug therapy ; Chlamydia Infections - microbiology ; Chlamydia trachomatis - drug effects ; Chlamydia trachomatis - growth & development ; Chlamydia trachomatis - isolation & purification ; Chlamydophila pneumoniae - drug effects ; Chlamydophila pneumoniae - growth & development ; Chlamydophila pneumoniae - isolation & purification ; Chlamydophila psittaci - drug effects ; Chlamydophila psittaci - growth & development ; Chlamydophila psittaci - isolation & purification ; Fluoroquinolones ; Humans ; Indoles - pharmacology ; Indoles - therapeutic use ; Macrolides ; Microbial Sensitivity Tests ; Quinolones - pharmacology ; Quinolones - therapeutic use ; Tetracyclines]]></subject><ispartof>Journal of antimicrobial chemotherapy, 2002-09, Vol.50 (3), p.407-410</ispartof><rights>Copyright Oxford University Press(England) Sep 2002</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-23d92e41c64c193ac499227db54265ce6b05a2c22998e20bb115195ede5f85403</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12205067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Donati, M.</creatorcontrib><creatorcontrib>Pollini, G. M.</creatorcontrib><creatorcontrib>Sparacino, M.</creatorcontrib><creatorcontrib>Fortugno, M. T.</creatorcontrib><creatorcontrib>Laghi, E.</creatorcontrib><creatorcontrib>Cevenini, R.</creatorcontrib><title>Comparative in vitro activity of garenoxacin against Chlamydia spp</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J. Antimicrob. Chemother</addtitle><description>The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Chlamydia Infections - drug therapy</subject><subject>Chlamydia Infections - microbiology</subject><subject>Chlamydia trachomatis - drug effects</subject><subject>Chlamydia trachomatis - growth & development</subject><subject>Chlamydia trachomatis - isolation & purification</subject><subject>Chlamydophila pneumoniae - drug effects</subject><subject>Chlamydophila pneumoniae - growth & development</subject><subject>Chlamydophila pneumoniae - isolation & purification</subject><subject>Chlamydophila psittaci - drug effects</subject><subject>Chlamydophila psittaci - growth & development</subject><subject>Chlamydophila psittaci - isolation & purification</subject><subject>Fluoroquinolones</subject><subject>Humans</subject><subject>Indoles - pharmacology</subject><subject>Indoles - therapeutic use</subject><subject>Macrolides</subject><subject>Microbial Sensitivity Tests</subject><subject>Quinolones - pharmacology</subject><subject>Quinolones - therapeutic use</subject><subject>Tetracyclines</subject><issn>0305-7453</issn><issn>1460-2091</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1rGzEQhkVJqZ2kl_6AsOTQQ2DrGX3t6hibJg4NBNq0lF6EVqt1ZHs_Iq2D_e-zwSaBXnIahvfhHeYh5AvCNwTFJktjJ-WqQi4-kDFyCSkFhUdkDAxEmnHBRuQ4xiUASCHzT2SElIIAmY3JdNbWnQmm908u8U3y5PvQJsYOu-93SVslCxNc026NHVKzML6JfTJ7WJt6V3qTxK47JR8rs47u82GekN9X3-9n8_T27vpmdnmbWo6iTykrFXUcreQWFTOWK0VpVhaCUymskwUIQy2lSuWOQlEgClTClU5UueDATsjXfW8X2seNi72ufbRuvTaNazdRZxQ4IJPvgpjzjOcyH8Dz_8BluwnN8ISmmEnJAF_OXuwhG9oYg6t0F3xtwk4j6Bf_evCv9_4H-OzQuClqV76hB-EDkO4BH3u3fc1NWOkhzYSe__2n8-mPqz_8J-hf7BmSKI6Z</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Donati, M.</creator><creator>Pollini, G. M.</creator><creator>Sparacino, M.</creator><creator>Fortugno, M. T.</creator><creator>Laghi, E.</creator><creator>Cevenini, R.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20020901</creationdate><title>Comparative in vitro activity of garenoxacin against Chlamydia spp</title><author>Donati, M. ; Pollini, G. M. ; Sparacino, M. ; Fortugno, M. T. ; Laghi, E. ; Cevenini, R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-23d92e41c64c193ac499227db54265ce6b05a2c22998e20bb115195ede5f85403</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Chlamydia Infections - drug therapy</topic><topic>Chlamydia Infections - microbiology</topic><topic>Chlamydia trachomatis - drug effects</topic><topic>Chlamydia trachomatis - growth & development</topic><topic>Chlamydia trachomatis - isolation & purification</topic><topic>Chlamydophila pneumoniae - drug effects</topic><topic>Chlamydophila pneumoniae - growth & development</topic><topic>Chlamydophila pneumoniae - isolation & purification</topic><topic>Chlamydophila psittaci - drug effects</topic><topic>Chlamydophila psittaci - growth & development</topic><topic>Chlamydophila psittaci - isolation & purification</topic><topic>Fluoroquinolones</topic><topic>Humans</topic><topic>Indoles - pharmacology</topic><topic>Indoles - therapeutic use</topic><topic>Macrolides</topic><topic>Microbial Sensitivity Tests</topic><topic>Quinolones - pharmacology</topic><topic>Quinolones - therapeutic use</topic><topic>Tetracyclines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Donati, M.</creatorcontrib><creatorcontrib>Pollini, G. M.</creatorcontrib><creatorcontrib>Sparacino, M.</creatorcontrib><creatorcontrib>Fortugno, M. T.</creatorcontrib><creatorcontrib>Laghi, E.</creatorcontrib><creatorcontrib>Cevenini, R.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Donati, M.</au><au>Pollini, G. M.</au><au>Sparacino, M.</au><au>Fortugno, M. T.</au><au>Laghi, E.</au><au>Cevenini, R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative in vitro activity of garenoxacin against Chlamydia spp</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J. Antimicrob. Chemother</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>50</volume><issue>3</issue><spage>407</spage><epage>410</epage><pages>407-410</pages><issn>0305-7453</issn><issn>1460-2091</issn><eissn>1460-2091</eissn><abstract>The in vitro susceptibilities of 33 isolates of Chlamydia trachomatis, Chlamydia pneumoniae and Chlamydia psittaci to a new quinolone drug, garenoxacin (BMS-284756), in comparison with levofloxacin, ciprofloxacin, doxycycline, erythromycin and roxithromycin, were determined. Garenoxacin was the most active of the quinolone drugs tested, with identical MIC and MBC, which ranged from 0.007 to 0.03 mg/L. The MIC and MBC of the other two quinolones tested, levofloxacin and ciprofloxacin, were also identical, ranging from 0.25 to 2 mg/L. The MICs and MBCs of doxycycline, erythromycin and roxithromycin were also determined.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>12205067</pmid><doi>10.1093/jac/dkf145</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2002-09, Vol.50 (3), p.407-410 |
| issn | 0305-7453 1460-2091 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72040136 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Free Full-Text Journals in Chemistry |
| subjects | Animals Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Chlamydia Infections - drug therapy Chlamydia Infections - microbiology Chlamydia trachomatis - drug effects Chlamydia trachomatis - growth & development Chlamydia trachomatis - isolation & purification Chlamydophila pneumoniae - drug effects Chlamydophila pneumoniae - growth & development Chlamydophila pneumoniae - isolation & purification Chlamydophila psittaci - drug effects Chlamydophila psittaci - growth & development Chlamydophila psittaci - isolation & purification Fluoroquinolones Humans Indoles - pharmacology Indoles - therapeutic use Macrolides Microbial Sensitivity Tests Quinolones - pharmacology Quinolones - therapeutic use Tetracyclines |
| title | Comparative in vitro activity of garenoxacin against Chlamydia spp |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A29%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20in%20vitro%20activity%20of%20garenoxacin%20against%20Chlamydia%20spp&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Donati,%20M.&rft.date=2002-09-01&rft.volume=50&rft.issue=3&rft.spage=407&rft.epage=410&rft.pages=407-410&rft.issn=0305-7453&rft.eissn=1460-2091&rft_id=info:doi/10.1093/jac/dkf145&rft_dat=%3Cproquest_cross%3E325349651%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=217663010&rft_id=info:pmid/12205067&rfr_iscdi=true |